1-6 of 6
Elizabeth T Chatburn, BS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Scott F Huntington, MD MPH, Stephen J. Schuster, MD, Wei He, PhD, Tong Shen, PhD, Heather Walker, MPH, CCRP, Laura Leary, Kylie Boyhen, Jennifer Gill, CRNP, Elizabeth T Chatburn, BS, Kaitlin Kennard, RN, BSN, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, David L. Porter, MD, Ellen Napier, NP, Mitchell E. Hughes, PharmD, Tanya Latorre, RN, Kristy Walsh, BS, Colleen Dorsey, BSN, RN, Jakub Svoboda, MD, Victoria Addis, MD, Barry Douglas Anderson, MD PhD, Emily Leblond, Yuqin Song, MD PhD, Jun Zhu, MD PhD, Lijuan Deng, MD PhD, Danielle M. Brander, MD, Wei Ding, MD PhD, Allison C. Rosenthal, DO, Han Tun, MD, Anthony R. Mato, MD MSCE
Journal: Blood
Blood (2018) 132 (Supplement 1): 5384.
https://doi.org/10.1182/blood-2018-99-112944
Published: 2018
Journal Articles

Simultaneous Global Phase I Studies of a Differentiated BTK Inhibitor, Dtrmwxhs-12, in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphomas

Yuqin Song, MD, Stephen J. Schuster, MD, Wei He, PhD, Jun Zhu, BS, Lijuan Deng, MD, Yingli Sun, MD, Ning Ding, MD, Xiaogan Wang, MD, Jennifer Gill, NP, MSN, Elizabeth T Chatburn, BS, Kaitlin Kennard, RN, BSN, Barry Douglas Anderson, MD PhD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, David L Porter, MD, Ellen Napier, NP, Mitchell E. Hughes, PharmD, BCPS, BCOP, Tanya Latorre, BSN, RN, Kristy Walsh, BS, Colleen Dorsey, BSN, Jakub Svoboda, MD, Victoria Addis, MD, Anthony R. Mato, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4056.
https://doi.org/10.1182/blood.V130.Suppl_1.4056.4056
Published: 2017
Journal Articles

KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy

Anthony R. Mato, MD, Bruce D. Cheson, MD, Nicole Lamanna, MD, John M. Pagel, MD PhD, Frederick Lansigan, MD, Paul M. Barr, MD, Jeffrey J. Pu, MD PhD, Colleen Dorsey, BSN, RN, Elizabeth T Chatburn, BS, Jakub Svoboda, MD, Stephen J. Schuster, MD, Eline Luning-Prak, MD PhD, Patricia Tsao, MD PhD, Andrea Sitlinger, MD, Chaitra S. Ujjani, MD, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Danielle M. Brander, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4314.
https://doi.org/10.1182/blood.V130.Suppl_1.4314.4314
Published: 2017
Journal Articles

Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL

Anthony R. Mato, MD, Colleen Dorsey, BSN, RN, Elizabeth T Chatburn, BS, Jessica Geoghegan, Stephen J. Schuster, MD, Jakub Svoboda, MD, Pamela S. Becker, MD PhD, Elise A. Chong, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Kaitlin Kennard, RN, BSN, Eline Luning-Prak, MD PhD, Patricia Tsao, MD PhD, Mitchell E. Hughes, PharmD, BCPS, BCOP, Michelle Purdom, PhDRN, Dana Paskalis, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Mazyar Shadman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3010.
https://doi.org/10.1182/blood.V130.Suppl_1.3010.3010
Published: 2017
Journal Articles

Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies

Anthony R. Mato, MD, John N. Allan, MD, John M. Pagel, MD PhD, Danielle M. Brander, MD, Brian T. Hill, MD PhD, Bruce D. Cheson, MD, Richard R. Furman, MD, Nicole Lamanna, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Ryan Jacobs, MD, Frederick Lansigan, MD, Paul M. Barr, MD, Mazyar Shadman, MD, Alan P Skarbnik, MD, Douglas F. Beach, MD, Jeffrey J. Pu, MD PhD, Alison R. Sehgal, MD, Allison M. Winter, MD, Clive S Zent, MD, Hande H. Tuncer, MD, Arun K Singavi, MD, Stephen J. Schuster, MD, Peter V. Pickens, MD, Nirav N Shah, MD, Annalynn Williams, MS, Christina Howlett, PharmD, BCOP, Hanna Weissbrot, BS, Naveed Ali, MD, Bhavisha Patel, MD, Krista Isaac, DO, MS, Joanna Rhodes, MD, Mitchell E. Hughes, PharmD, BCPS, BCOP, Sirin Khajavian, MD, Elizabeth T Chatburn, BS, Andrea Sitlinger, MD, Eve Tranchito, BS, Erica Bharat Bhavsar, BS, Neil Bailey, MS, Timothy F. Burns, MD, Melissa Yacur, MD, Mansi Malhotra, BS, Sasanka Handunnetti, MD, Kaitlin Kennard, RN, BSN, Chadi Nabhan, MD MBA, FACP, Chaitra S. Ujjani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3011.
https://doi.org/10.1182/blood.V130.Suppl_1.3011.3011
Published: 2017
Journal Articles

Clinical Outcomes of Anti PD-1 Immunotherapy in Patients with Relapsed/Refractory Non Hodgkin Lymphomas

Mitchell E. Hughes, PharmD, BCPS, BCOP, Christopher Jensen, MD, Jakub Svoboda, MD, Lauren Elizabeth Strelec, BA, Matthew R. Youngman, BS, Stephen J. Schuster, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Donald Edward Tsai, MD PhD, David Michael Mintzer, MD, Jennifer Gill, NP, MSN, Colleen Dorsey, BSN, Kaitlin Kennard, RN, BSN, Elizabeth T Chatburn, BS, Joanna Rhodes, MD, Krista Isaac, DO, MS, Kristy Walsh, BS, Tanya Latorre, BSN, RN, Kaley Piersanti, BS, Evan Bannister, BS, Colleen Timlin, PharmD, BCOP, Donna Capozzi, PharmD, BCOP, Anthony R. Mato, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1575.
https://doi.org/10.1182/blood.V130.Suppl_1.1575.1575
Published: 2017